Hot Investor Mandate: China-Based Public Biopharma Company Seeks Licensing Opportunities in Oncology, Ophthalmology, and Nephrology, Most Interested in US/EU Companies

24 Mar

A public biopharmaceutical company with over 20 years operation in China’s pharmaceutical industry is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives. The firm is interested in in-licensing clinical stage assets for development, while collaborative R&D can also be considered. Typical equity investments range from $2-3M per deal. The firm has partnered with companies in Japan, the US and Europe. The firm is currently looking for new opportunities globally with a focus on US and EU.

Currently, the firm is seeking therapeutics in oncology, ophthalmology, and nephrology. The firm is most interested in new formulation and is open to small molecule, biologics, biosimilars, and repurposed drugs. The firm currently focuses on assets in phase 2 clinical trials, while it can consider assets from pre-clinical to on-market stages.

The firm is seeking innovative assets that address large unmet medical need. The firm generally seeks development and/or commercialization rights in China and Southeast Asia.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: